Dactolisib

Manufactured by Santa Cruz Biotechnology

Sourced in United States

Dactolisib is a small molecule inhibitor that targets the mammalian target of rapamycin (mTOR) signaling pathway. mTOR is a serine/threonine protein kinase that regulates cell growth, proliferation, and survival. Dactolisib inhibits both mTORC1 and mTORC2 complexes, which are involved in various cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using dactolisib

Cell Proliferation Assay with Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dulbeccos Modified Eagle Medium (DMEM)/Nutrient Mixture F-12 Ham, Dimethyl Sulfoxide (DMSO), Ethylenediaminetetraacetic Acid (EDTA), Cell Growth Determination Kit MTT based [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] were purchased from Sigma-Aldrich (Germany), Fetal Bovine Serum (FBS), Penicillin/Streptomycin antibiotics, Trypsin, Phosphate-buffered saline (PBS) were obtained from Gibco by Life TechnologiesTM, Cell Lysis Buffer was provided by Invitrogen, Life Tehnologies, USA.
SU1498 (VEGFR2 selective inhibitor) and Dactolisib (dual PI3K/mTOR inhibitor) were acquired from Santa Cruz Biotechnologies, AG1433 (PDGFR-β and a weak inhibitor of angiogenesis and VEGFR2) were obtained from Sigma-Aldrich.

PURCARU S.O., TACHE D.E., SERBAN F., FOLCUTI R.M., GEORGESCU A.M., STOVICEK P.O., DANCIULESCU M.M., TATARANU L.G, & DRICU A. (2015). Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma. Current Health Sciences Journal, 41(4), 325-332.

+ Open protocol

+ Expand

Anticancer Drug Library Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols

A custom‐arrayed anticancer library was used (Bezu et al, 2018). In addition, bortezomib (5043140001); cisplatin (C2210000); crizotinib (PZ0191); dactinomycin (A1410); daunorubicin (D0125000); docetaxel (01885); doxorubicin (D1515); epirubicin (E9406); flavopiridol (F30055); ISRIB (SML0843); β‐lapachone (L2037); mitoxantrone (M6545); mycophenolate mofetil (SML0284); nonoxynol‐9 (542334); paclitaxel (T7191); thapsigargin (T9033); tunicamycin (T7765); vinblastine sulfate (V1377); and vincristine sulfate (V0400000) have been bought from Sigma‐Aldrich. Dactolisib (BEZ235) (sc‐364429) came from Santa Cruz biotechnology (Dallas, TX, USA). Oxaliplatin came from Accord Healthcare (Ahmedabad, India). Topotecan (609699), 7‐hydroxystausporine (UCN‐01) (72271), becatecarin (101524), 5‐fluorodeoxycytidine (B86) (515328), and RH‐1 (394347) were kindly provided by the National Cancer Institute (NCI). Lurbinectedin (PM01183) came from PharmaMar (Madrid, Spain).

Humeau J., Sauvat A., Cerrato G., Xie W., Loos F., Iannantuoni F., Bezu L., Lévesque S., Paillet J., Pol J., Leduc M., Zitvogel L., de Thé H., Kepp O, & Kroemer G. (2020). Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Molecular Medicine, 12(5), e11622.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!